Sanofi Suit Against Novo Narrowed

The lawsuit Sanofi slapped Novo Nordisk with over an inflammatory national advertising campaign has been narrowed by a federal judge.

Sanofi accused Novo Nordisk of falsely claiming Sanofi's insulin drugs Lantus and Toujeo would no longer be available after their removal from the CVS formulary so it could promote its competing drug, Tresiba, in a five-count lawsuit filed late last year.

But U.S. District Judge Michael Shipp ruled July 10 that one of Sanofi's claims brought under a state law, the New Jersey Consumer Fraud Act, which was meant to protect consumers not competitors and should be dismissed.